Gilead Sciences to acquire Kite Pharma for $11.9bn

29-08-2017

Gilead Sciences to acquire Kite Pharma for $11.9bn

cecilie_arcurs / iStockphoto.com

Gilead Sciences is to acquire Kite Pharma for $11.9 billion, after the deal was unanimously approved by both companies’ boards of directors.


Gilead Sciences, Kite Pharma, M&A, mergers and acquisitions, FDA, axicabtagene ciloeucel (axi-cel), CAR T therapy

LSIPR